Table 4.
Predictors of recurrence and overall survival after radiofrequency ablation
| Variables | Recurrence
|
Overall survival
|
||||
|---|---|---|---|---|---|---|
| Univariate
|
Multivariate
|
Univariate
|
Multivariate
|
|||
| P-value | P-value | HR (95% CI) | P-value | P-value | HR (95% CI) | |
| Demographic variables | ||||||
| Age, years | NS | 0.054 | ||||
| Male sex | NS | NS | ||||
| Body mass index, kg/m2 | NS | NS | ||||
| Etiology, HBV/HCV/NBNC | 0.093 | NS | ||||
| Antiviral therapy in HBV/HCV | NS | NS | ||||
| Diabetes mellitus | NS | NS | ||||
| Previous anti-HCC treatment history | 0.001 | 0.016 | 3.115 (1.238–7.842) | NS | ||
| Laboratory variables | ||||||
| Alanine aminotransferase, IU/L | NS | |||||
| Serum albumin, mg/dL | NS | NS | ||||
| Total bilirubin, mg/dL | 0.029 | 0.169 | 2.167 (0.719–6.529) | 0.002 | 0.009 | 5.200 (1.508–17.930) |
| Prothrombin time, INR | NS | NS | ||||
| Serum creatinine, mg/dL | NS | NS | ||||
| Platelet count,/μL | 0.003 | 0.190 | 1.000 (1.000–1.000) | NS | ||
| Spleen size, cm | 0.001 | 0.329 | 1.134 (0.881–1.461) | 0.021 | 0.597 | 1.081 (0.809–1.446) |
| Tumor variables | – | |||||
| Alpha-fetoprotein, ng/mL | NS | – | NS | |||
| Des-gamma carboxyl prothrombin, ng/mL | NS | 0.075 | ||||
| Tumor number | 0.049 | 0.155 | 1.900 (0.785–4.598) | NS | ||
| Maximal tumor size, cm | NS | NS | ||||
| Total tumor size, cm | 0.054 | NS | ||||
| Noninvasive fibrosis prediction tools | ||||||
| Liver stiffness ≥13 kPa | <0.001 | 0.016 | 3.115 (1.238–7.842) | 0.019 | 0.037 | 9.834 (1.148–84.211) |
| APRI | NS | NS | ||||
Abbreviations: APRI, aspartate-to-platelet ratio index; CI, confidence interval; HBV, hepatitis B virus; HCC, hepatocellular carcinoma; HCV, hepatitis C virus; NBNC, non-B and non-C; HR, hazard ratio; INR, international normalized ratio; NS, not significant.